Galimedix Therapeutics
Manufacturing · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3704 Calvend Ln, Kensington, Maryland, 2...Website
www.galimedix.comRevenue
$5.3 MillionIndustry
About Galimedix Therapeutics
Galimedix Therapeutics is focused on developing innovative drugs to treat neurodegenerative diseases, particularly those involving amyloid beta, such as dry age-related macular degeneration (AMD), glaucoma, and Alzheimer's disease. Their lead candidate, GAL-101, is currently in Phase 2 clinical testing for dry AMD and aims to provide patient-friendly administration options like eye drops and oral tablets. The company emphasizes creating well-tolerated treatments with fewer side effects compared to existing options. Galimedix is dedicated to improving the lives of millions of patients worldwide by addressing the root causes of these diseases.Explore more
Galimedix Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Galimedix Therapeutics
Compare insights from companies similar to Galimedix Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Galimedix Therapeutics Tech Stack
A closer look at the technologies used by Galimedix Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Galimedix Therapeutics
Sign Up For FreeTo access detailed company insights
Galimedix Therapeutics is focused on developing innovative drugs to treat neurodegenerative diseases, particularly those involving amyloid beta, such as dry age-related macular degeneration (AMD), glaucoma, and Alzheimer's disease. Their lead candidate, GAL-101, is currently in Phase 2 clinical testing for dry AMD and aims to provide patient-friend... Read More
